查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1929649

口服胜肽類藥物市場按劑型、分子類型、通路、應用和最終用戶分類，全球預測（2026-2032年）

Oral Peptide Drugs Market by Form, Molecule Type, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，口服胜肽類藥物市值將達到 48.4 億美元，到 2026 年將成長至 52 億美元，到 2032 年將達到 76.9 億美元，複合年成長率為 6.82%。

關鍵市場統計數據
基準年 2025 48.4億美元
預計年份：2026年 52億美元
預測年份 2032 76.9億美元
複合年成長率 (%) 6.82%

對科學突破、臨床需求和醫療服務挑戰的全面審視正在重塑口服胜肽療法和相關人員的優先事項。

口服胜肽類藥物代表生物活性分子遞送方式的革命性轉變，傳統上此類藥物只能透過腸外途徑給藥。近年來，製劑科學、滲透增強技術和遞送平台的進步，已將胜肽類藥物的潛力轉化為可行的臨床治療選擇，從而提高了患者的依從性，並開闢了新的治療模式。本文概述了目前口服胜肽類藥物的技術、商業性和監管格局，並指出了創新者必須克服的關鍵挑戰，才能將分子層面的療效轉化為實際臨床應用。

口服給藥技術的進步、以患者為中心的護理模式以及不斷變化的監管要求，如何加速肽類藥物領域的策略調整

口服胜肽類藥物的研發格局正經歷一系列變革性轉變，這些轉變正在改變打入市場策略和投資重點。其中最主要的變化是口服給藥技術的成熟，這些技術能夠減少酵素分解並提高黏膜滲透性，從而拓展胜肽類藥物的治療潛力，使其不再局限於特定適應症。這一發展趨勢促使製藥公司重新評估其資產組合，並將重點放在那些口服製劑能夠帶來顯著臨床差異化的分子上。

評估截至2025年的關稅調整如何改變了口服胜肽價值鏈的籌資策略、製造地選擇和商業協議。

到2025年，一系列關稅調整的累積影響正在顯著改變企業採購關鍵原料、建立製造地以及談判商業條款的方式。某些化學前驅物、添加劑和設備的進口關稅提高，凸顯了供應鏈韌性和成本透明度的重要性。因此，企業在選擇供應商時越來越重視關稅風險，透過談判簽訂長期合約來穩定到岸成本，並優先考慮擁有多元化物流路線和近岸生產能力的供應商。

基於深度細分的洞察，可最佳化針對不同治療標靶、製劑形式、通路、臨床環境和分子類別的開發和商業化方案。

細分市場分析揭示了不同治療標靶、劑型、通路、終端用戶環境和分子類別所帶來的獨特機會和技術要求。依照治療應用進行考量，可以發現顯著差異：針對心血管疾病的項目需要能夠整合到慢性病治療路徑中的製劑和給藥方案；糖尿病的研發涵蓋DPP-4抑製劑、GLP-1類似物和胰島素肽，每種藥物都面臨著獨特的吸收和給藥挑戰；胃腸道疾病的研發優先考慮腸道穩定性和耐受性；而腫瘤藥物，例如激酶和腫瘤藥物，例如激酶和疫苗安全性的證據優先性證據。這些治療領域的細微差別直接影響製劑的選擇和臨床開發計劃。

區域監管環境、生產優勢和疾病負擔如何影響美洲、歐洲、中東和非洲以及亞太地區口服胜肽的商業化策略

區域趨勢持續影響口服胜肽類藥物的推廣應用，在美洲、歐洲、中東和非洲以及亞太市場，各市場面臨不同的機會和挑戰。在美洲，創新中心和集中式支付系統促進了口服生物利用度高的胜肽類藥物的早期應用，這些藥物在提高患者依從性和治療效果方面展現出顯著優勢；同時，完善的監管路徑和商業基礎設施也支持臨床差異化候選藥物的快速規模化生產。在歐洲、中東和非洲，由於法規環境的多樣性和報銷方式的波動，需要製定個人化的市場進入策略，以反映各國的衛生技術評估（HTA）流程和價格敏感度。

在不斷發展的口服胜肽領域，繪製出策略聯盟、生產規模化投資和授權授權集中形成競爭優勢的領域圖譜。

主要企業的活動特徵是策略聯盟、平台授權和對專業生產和製劑技術的定向投資。領先的製藥和生物技術公司正大力投資適用於多種胜肽類藥物的口服給藥平台，而專業技術公司則專注於賦形劑、滲透促進劑和包封方法，以實現全身暴露。合約開發和生產組織 (CDMO) 正在擴大無菌和非無菌生產能力，以滿足胜肽類原料藥和最終製劑的生產需求，而服務供應商透過降低規模化生產風險的整合開發路徑來實現差異化競爭優勢。

為幫助經營團隊透過平台投資、供應鏈韌性和基於證據的准入策略獲得競爭優勢，提供切實可行的策略建議。

產業領導者應採取整合、多維度的策略，將科學進步轉化為永續的市場地位。優先投資於可廣泛適用於各類胜肽的口服給藥平台，同時推進分子特異性製劑的研發，以臨床實驗。加強與供應商的關係並實現採購地點的多元化，有助於降低關稅和物流風險；而對區域生產和加工能力的定向投資，則可帶來成本和前置作業時間的優勢。

我們採用嚴謹的多方法研究途徑，結合專家訪談、文獻綜合、監管文件審查和情境檢驗，來支持我們的策略結論。

支持這些發現的研究整合了來自多個資訊來源的定性和定量方法，以驗證結果並最大限度地減少偏差。主要資料來源包括對研發主管、監管專家、生產主管、支付方和臨床研究人員的結構化訪談，並輔以對同行評審文獻、監管指導文件和公司資訊披露的綜合分析。跨治療領域和分子類型的比較分析採用了一致的框架來評估技術風險、臨床開發複雜性和商業性考慮。

結論概述了一個切實可行的藍圖，該路線圖結合了製劑創新、監管參與和商業性執行，以實現口服胜肽類藥物的潛力。

總之，在遞送科學的快速發展、策略夥伴關係以及以商業性為中心的醫療治療方法理念的推動下，口服胜肽類藥物正從概念性潛力走向切實可行的臨床和商業現實。該領域的成功取決於一種整合策略，即根據不同治療領域和區域市場的獨特需求，將分子選擇、製劑創新、監管策略和供應鏈設計相結合。積極應對技術風險、及早與支付方和監管機構溝通並建立靈活的生產體系的相關人員，將更有利於把科學進步轉化為持續的市場進入和患者獲益。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 口服胜肽類藥物市場（依劑型分類）

  • 膠囊
  • 口服液
  • 口服懸浮液
  • 藥片

9. 依分子類型分類的口服胜肽類藥物市場

  • 修飾胜肽
  • 天然胜肽
  • 胜肽類似物

第10章 口服胜肽類藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 依應用分類的口服胜肽藥物市場

  • 心血管疾病
  • 糖尿病
    • DPP-4抑制劑
    • GLP-1類似物
    • 胰島素胜肽
  • 消化系統疾病
  • 腫瘤學
    • 激酶抑制劑
    • 胜肽疫苗

第12章 依最終用戶分類的口服胜肽類藥物市場

  • 診所
  • 居家醫療環境
  • 醫院
  • 專業醫療中心

第13章 各地區口服胜肽類藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 口服胜肽類藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國口服胜肽類藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國口服胜肽類藥物市場

第17章：中國口服胜肽類藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocon
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • i2o Therapeutics
  • Intract Pharma
  • Ipsen SA
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Protagonist Therapeutics, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-0A380695186C

The Oral Peptide Drugs Market was valued at USD 4.84 billion in 2025 and is projected to grow to USD 5.20 billion in 2026, with a CAGR of 6.82%, reaching USD 7.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.84 billion
Estimated Year [2026] USD 5.20 billion
Forecast Year [2032] USD 7.69 billion
CAGR (%) 6.82%

A comprehensive orientation to the scientific breakthroughs, clinical imperatives, and healthcare delivery challenges reshaping oral peptide therapeutics and stakeholder priorities

Oral peptide therapeutics represent a pivotal shift in the delivery of biologically active molecules historically constrained to parenteral administration. Recent advances in formulation science, permeation enhancement, and delivery platforms have transformed the promise of peptides into practical clinical options, enabling sustained patient adherence and new therapeutic paradigms. This introduction frames the technical, commercial, and regulatory contours that define the current landscape and identifies the primary challenges that innovators must overcome to translate molecular efficacy into real-world outcomes.

Clinicians and development teams now confront a distinct set of priorities: preserving molecular integrity through the gastrointestinal tract, achieving clinically meaningful systemic exposure without invasive devices, and ensuring consistent patient-centric dosing regimens. Concurrently, payers and healthcare systems are recalibrating evaluation frameworks to balance acquisition cost with downstream adherence and outcomes. By articulating the interplay between scientific innovation and healthcare delivery, this section sets the stage for the deeper analysis that follows, highlighting why oral peptide programs require integrated strategies across formulation development, clinical evidence generation, manufacturing scalability, and market access planning.

How advances in oral delivery technologies, patient-centric care models, and evolving regulatory expectations are accelerating strategic realignment across the peptide therapeutics sector

The landscape of oral peptide drug development is being reshaped by a series of transformative shifts that are altering go-to-market strategies and investment priorities. Chief among these shifts is the maturation of oral delivery technologies that mitigate enzymatic degradation and improve mucosal permeability, thereby expanding the therapeutic potential of peptides beyond niche indications. This evolution is prompting pharmaceutical organizations to re-evaluate asset portfolios, prioritizing molecules that can deliver meaningful clinical differentiation when formulated for oral administration.

Another major shift is the move toward patient-centric care models that reward oral options with improved convenience and adherence, which in turn influence payer dialogues and formulary decisions. Strategic partnerships between innovators, contract development and manufacturing organizations, and specialized excipient providers are accelerating time-to-proof-of-concept and de-risking scale-up pathways. Simultaneously, regulatory expectations have evolved to place greater weight on robust pharmacokinetic characterization and real-world adherence data, creating new evidence requirements for market entry. Collectively, these trends are converging to make oral peptides a high-priority axis of innovation, while also raising the bar for cross-functional coordination across R&D, regulatory, commercial, and supply chain teams.

Assessing how tariff adjustments up to 2025 have reshaped sourcing strategies, manufacturing siting decisions, and commercial contracting across the oral peptide value chain

The cumulative impact of tariff changes instituted through 2025 has introduced measurable shifts in how organizations source key inputs, structure manufacturing footprints, and negotiate commercial terms. Elevated import duties on select chemical precursors, excipients, and equipment have amplified the importance of supply chain resilience and cost transparency. As a result, companies are increasingly factoring tariff exposure into supplier selection, negotiating longer-term contracts to stabilize landed cost, and prioritizing suppliers with diversified logistics corridors and near-shore capabilities.

These trade-related pressures are also incentivizing strategic investments in domestic manufacturing capacity and in-country finishing operations to reduce exposure to cross-border tariff volatility. For some developers, higher import costs have prompted a re-examination of formulation strategies to identify alternative excipients or to adopt manufacturing technologies that consolidate steps and reduce reliance on imported intermediates. In parallel, procurement and commercial teams are revisiting pricing models and contracting structures to preserve affordability for healthcare systems while maintaining viable margins. The cumulative result is a supply chain that is becoming more regionally oriented, more collaborative, and more focused on operational flexibility to absorb policy-driven disruptions.

Deep segmentation-driven insights that align therapeutic targets, formulation formats, distribution pathways, care settings, and molecule classes to optimize development and commercialization choices

Segmentation analysis reveals differentiated opportunities and technical requirements across therapeutic targets, dosage forms, channels of distribution, end-user settings, and molecular classes. When viewed by therapeutic application, notable distinctions emerge: programs targeting cardiovascular disorders require formulations and regimens that integrate with chronic care pathways; diabetes-focused development spans DPP-4 inhibitors, GLP-1 analogues, and insulin peptides each of which presents unique absorption and dosing challenges; gastrointestinal disorders prioritize local gut stability and tolerability; and oncology assets such as kinase inhibitors and peptide vaccines impose stringent efficacy and safety evidence expectations. These therapeutic nuances directly influence formulation choices and clinical development planning.

Form-related segmentation highlights that capsules, oral solutions, oral suspensions, and tablets each present trade-offs between stability, manufacturability, and patient acceptability, with selection driven by molecule properties and intended use. Distribution channel dynamics differ materially across hospital pharmacies, online pharmacies, and retail pharmacies, affecting procurement cycles, cold chain practices, and patient access models. End-user segmentation into clinics, home care settings, hospitals, and specialty centers underscores divergent requirements for dosing support, adherence monitoring, and provider education. Finally, molecule type-whether modified peptides, native peptides, or peptide mimetics-dictates chemical stability, susceptibility to enzymatic degradation, and formulation strategy. Integrating these segmentation lenses enables more precise targeting of development investments, regulatory strategies, and commercialization plans tailored to therapeutic class and care setting realities.

How regional regulatory landscapes, manufacturing strengths, and disease burdens across the Americas, Europe Middle East & Africa, and Asia-Pacific are directing oral peptide commercialization strategies

Regional dynamics continue to shape the trajectory of oral peptide adoption with distinct opportunities and constraints across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, innovation centers and concentrated payer systems favor early adoption of orally bioavailable peptides that demonstrate clear improvements in adherence and outcomes, while regulatory pathways and commercial infrastructure support rapid scale-up for clinically differentiated candidates. Across Europe, Middle East & Africa, heterogeneous regulatory environments and variable reimbursement approaches necessitate tailored market access strategies that reflect national HTA processes and pricing sensitivities.

The Asia-Pacific region combines strong manufacturing capacity with growing clinical demand, creating fertile ground for both originator companies and regional developers. High disease prevalence for indications such as diabetes and cardiovascular disorders heightens the strategic importance of cost-effective oral options and fosters partnerships between global firms and local manufacturers. Across all regions, geopolitical dynamics, logistics networks, and local regulatory expectations shape decisions on where to locate manufacturing and how to sequence launches, making region-specific planning an essential component of any global oral peptide strategy.

Mapping where strategic partnerships, manufacturing scale-up investments, and platform licensing are concentrating competitive advantage in the evolving oral peptide sector

Key company activity is characterized by strategic alliances, platform licensing, and targeted investments in specialized manufacturing and formulation capabilities. Leading pharmaceutical and biotechnology firms are placing priority bets on oral delivery platforms that can be applied across multiple peptide classes, while specialized technology firms focus on excipients, permeation enhancers, and encapsulation approaches that unlock systemic exposure. Contract development and manufacturing organizations are expanding aseptic and non-aseptic capabilities to accommodate peptide API and finished-dose production, and service providers are differentiating through integrated development pathways that reduce scale-up risk.

Competitive dynamics also reflect a bifurcation between large incumbents with portfolio breadth and agility, and nimble biotech firms that advance novel molecules or delivery modalities through early clinical validation. Licensing transactions and strategic collaborations play a central role in accelerating development timelines, enabling innovators to combine molecular expertise with specialized formulation know-how. Across the ecosystem, companies that can demonstrate reproducible manufacturing, robust clinical evidence, and a clear route to patient access are best positioned to convert scientific promise into commercial success.

Actionable strategic recommendations for executives to secure competitive advantage through platform investments, supply chain resilience, and evidence-driven access strategies

Industry leaders should adopt an integrated, multi-dimensional strategy to convert scientific advances into durable market positions. Prioritize investments in oral delivery platforms that offer broad applicability across peptide classes, while simultaneously advancing molecule-specific formulation development to de-risk pivotal studies. Strengthening supplier relationships and diversifying sourcing footprints will mitigate tariff and logistics risk, and targeted investments in regional manufacturing or finishing capabilities can provide cost and lead-time advantages.

Commercial strategies should align with payer and provider expectations by generating evidence that links oral administration to real-world adherence and outcomes. Engage early with regulators and health technology assessors to clarify evidence requirements and to design studies that address both efficacy and pragmatic usage. Form cross-functional teams that include formulation scientists, clinical development leads, regulatory experts, and commercial strategists to ensure decision-making reflects end-to-end implications. Finally, pursue flexible partnership models that enable rapid access to specialized capabilities while preserving optionality for future scale-up and geographic expansion.

A rigorous multi-method research approach combining expert interviews, literature synthesis, regulatory document review, and scenario validation to underpin strategic conclusions

The research underpinning these insights integrates multi-source qualitative and quantitative techniques designed to triangulate findings and minimize bias. Primary inputs include structured interviews with R&D leaders, regulatory specialists, manufacturing heads, payers, and clinical investigators, complemented by synthesis of peer-reviewed literature, regulatory guidance documents, and company disclosures. Comparative analysis across therapeutic areas and molecule types employed a consistent framework to evaluate technical risk, clinical development complexity, and commercial considerations.

Validation steps included cross-referencing interview inputs with observable regulatory filings and manufacturing announcements, conducting scenario testing for supply chain and tariff impacts, and soliciting external expert review to challenge assumptions. Limitations of the methodology are acknowledged: the rapidly evolving technology landscape means some platform capabilities may progress faster than documented public disclosures, and proprietary commercial terms remain confidential. Nonetheless, the methodological rigor applied here supports robust, actionable insights for decision-makers navigating oral peptide development and commercialization.

Concluding synthesis that connects formulation breakthroughs, regulatory engagement, and commercial execution into a practical roadmap for realizing the potential of oral peptide medicines

In conclusion, oral peptide therapeutics are transitioning from conceptual promise to tangible clinical and commercial reality, driven by rapid advances in delivery science, strategic partnerships, and evolving healthcare priorities that favor patient-centric regimens. Success in this space will depend on integrated approaches that align molecule selection, formulation innovation, regulatory strategy, and supply chain design with the distinct demands of therapeutic area and regional markets. Stakeholders that proactively address technical risks, engage payers and regulators early, and structure flexible manufacturing footprints will be best positioned to translate scientific progress into durable market access and patient impact.

The pathway forward demands both technological expertise and commercial acuity: companies must combine rigorous clinical evidence generation with pragmatic commercialization plans that reflect regional dynamics and payer expectations. For leaders seeking to act on the opportunities described herein, the full report provides deeper scenario analysis, competitive benchmarking, and tactical guidance to operationalize these conclusions and accelerate value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Peptide Drugs Market, by Form

  • 8.1. Capsules
  • 8.2. Oral Solutions
  • 8.3. Oral Suspensions
  • 8.4. Tablets

9. Oral Peptide Drugs Market, by Molecule Type

  • 9.1. Modified Peptides
  • 9.2. Native Peptides
  • 9.3. Peptide Mimetics

10. Oral Peptide Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies

11. Oral Peptide Drugs Market, by Application

  • 11.1. Cardiovascular Disorders
  • 11.2. Diabetes
    • 11.2.1. DPP-4 Inhibitors
    • 11.2.2. GLP-1 Analogues
    • 11.2.3. Insulin Peptides
  • 11.3. Gastrointestinal Disorders
  • 11.4. Oncology
    • 11.4.1. Kinase Inhibitors
    • 11.4.2. Peptide Vaccines

12. Oral Peptide Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care Settings
  • 12.3. Hospitals
  • 12.4. Specialty Centers

13. Oral Peptide Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Peptide Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Peptide Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Peptide Drugs Market

17. China Oral Peptide Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amgen Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Biocon
  • 18.9. Bristol-Myers Squibb Company
  • 18.10. Eli Lilly and Company
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. i2o Therapeutics
  • 18.13. Intract Pharma
  • 18.14. Ipsen S.A.
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Novo Nordisk A/S
  • 18.18. Oramed Pharmaceuticals Inc.
  • 18.19. Pfizer Inc.
  • 18.20. Protagonist Therapeutics, Inc.
  • 18.21. Sanofi S.A.
  • 18.22. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL PEPTIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL PEPTIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY MODIFIED PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY NATIVE PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE MIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GLP-1 ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY INSULIN PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 158. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. GCC ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL ORAL PEPTIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA ORAL PEPTIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)